<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03628339</url>
  </required_header>
  <id_info>
    <org_study_id>MS200095_0030</org_study_id>
    <secondary_id>2017-005055-92</secondary_id>
    <nct_id>NCT03628339</nct_id>
  </id_info>
  <brief_title>Effect of Tepotinib on Pharmacokinetics (PK) of Cytochrome P450 (CYP) 3A Substrate Midazolam</brief_title>
  <official_title>Phase 1, Open-label, Single Sequence, Two-Period Crossover Trial to Evaluate the Effect of Tepotinib on Cytochrome P450 (CYP) 3A by Investigating the Pharmacokinetics of the CYP3A Substrate Midazolam in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the effect of tepotinib on the PK of the CYP3A substrate midazolam
      determined from concentrations of midazolam and its main metabolite 1-hydroxymidazolam in
      healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Actual">October 30, 2018</completion_date>
  <primary_completion_date type="Actual">October 25, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a single sequence cross-over trial.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Midazolam</measure>
    <time_frame>Pre-dose up to 48 hours post-dose on Day 1 of Period 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Midazolam</measure>
    <time_frame>Pre-dose up to 48 hours post-dose on Day 11 of Period 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Midazolam</measure>
    <time_frame>Pre-dose up to 48 hours post-dose on Day 1 of Period 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Midazolam</measure>
    <time_frame>Pre-dose up to 48 hours post-dose on Day 11 of Period 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Midazolam</measure>
    <time_frame>Pre-dose up to 48 hours post-dose on Day 1 of Period 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Midazolam</measure>
    <time_frame>Pre-dose up to 48 hours post-dose on Day 11 of Period 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) of Midazolam</measure>
    <time_frame>Pre-dose up to 48 hours post-dose on Day 1 of Period 1 and Day 11 of Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (t1/2) of Midazolam</measure>
    <time_frame>Pre-dose up to 48 hours post-dose on Day 1 of Period 1 and Day 11 of Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Midazolam Metabolite 1-hydroxymidazolam</measure>
    <time_frame>Pre-dose up to 48 hours post-dose on Day 1 of Period 1 and Day 11 of Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Midazolam Metabolite 1-hydroxymidazolam</measure>
    <time_frame>Pre-dose up to 48 hours post-dose on Day 1 of Period 1 and Day 11 of Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Midazolam Metabolite 1-hydroxymidazolam</measure>
    <time_frame>Pre-dose up to 48 hours post-dose on Day 1 of Period 1 and Day 11 of Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) of Midazolam Metabolite 1-hydroxymidazolam</measure>
    <time_frame>Pre-dose up to 48 hours post-dose on Day 1 of Period 1 and Day 11 of Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (t1/2) of Midazolam Metabolite 1-hydroxymidazolam</measure>
    <time_frame>Pre-dose up to 48 hours post-dose on Day 1 of Period 1 and Day 11 of Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Ratio of Midazolam and Midazolam Metabolite 1-hydroxymidazolam</measure>
    <time_frame>Pre-dose up to 48 hours post-dose on Day 1 of Period 1 and Day 11 of Period 2</time_frame>
    <description>Metabolic ratio will be calculated as AUC 0-infinity of midazolam divided by AUC 0-infinity of 1-hydroxymidazolam.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to Day 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Laboratory Assessments, 12-lead Electrocardiogram (ECG) Findings and Vital Signs</measure>
    <time_frame>Day 1 up to Day 20 (Period 2)</time_frame>
    <description>Number of participants with clinically significant changes will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Midazolam, then tepotinib followed by midazolam + tepotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of midazolam on Day 1 of treatment period 1 followed by daily single oral dose of tepotinib from Day 1 to Day 10 of treatment period 2 and then co-administration of tepotinib and midazolam on Day 11 of treatment period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Participant will receive single oral dose of midazolam on Day 1 of treatment period 1 and co-administration of tepotinib and midazolam on Day 11 of treatment period 2.</description>
    <arm_group_label>Midazolam, then tepotinib followed by midazolam + tepotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tepotinib</intervention_name>
    <description>Participants will receive single oral dose of tepotinib for 10 days in treatment period 2.</description>
    <arm_group_label>Midazolam, then tepotinib followed by midazolam + tepotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy participants of non-child bearing potential

          -  Body weight between 50 to 100 kilogram (kg)

          -  Body mass index (BMI) between 18.5 and 29.9 kilogram per meter square (kg/m^2)

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Participation in a clinical study within 60 days prior to first drug administration

          -  Whole blood donation or loss of greater than 450 milliliter (mL) within 60 days prior
             to first drug administration

          -  Any surgical or medical condition, or any other significant disease that could
             interfere with the study objectives, conduct, or evaluation

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nuvisan GmbH</name>
      <address>
        <city>Neu-Ulm</city>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>August 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>June 21, 2019</last_update_submitted>
  <last_update_submitted_qc>June 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tepotinib</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Cytochrome P450</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

